Brokerages Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.76) EPS

Aptevo Therapeutics Inc (NASDAQ:APVO) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $6.00 for the company and are anticipating that the company will post ($0.76) EPS for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 173 out of 265 based on the ratings given to related companies.

Separately, Roth Capital started coverage on Aptevo Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $12.00 target price on the stock.



APVO opened at $4.10 on Friday. Aptevo Therapeutics has a 12 month low of $1.15 and a 12 month high of $4.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.08 and a current ratio of 5.14. The company has a market capitalization of $80.02, a P/E ratio of -2.68 and a beta of 0.68.

In related news, insider Marvin L. White sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $2.93, for a total value of $293,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 15.60% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of APVO. Renaissance Technologies LLC boosted its stake in Aptevo Therapeutics by 411.8% during the 4th quarter. Renaissance Technologies LLC now owns 428,400 shares of the biotechnology company’s stock valued at $1,816,000 after purchasing an additional 344,700 shares in the last quarter. Victory Capital Management Inc. bought a new position in Aptevo Therapeutics during the 4th quarter valued at $827,000. Virtu Financial LLC bought a new position in Aptevo Therapeutics during the 4th quarter valued at $690,000. Finally, Acadian Asset Management LLC boosted its stake in Aptevo Therapeutics by 87.2% during the 4th quarter. Acadian Asset Management LLC now owns 67,799 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 31,578 shares in the last quarter. 33.04% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.76) EPS” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://dakotafinancialnews.com/2018/04/13/brokerages-anticipate-aptevo-therapeutics-inc-apvo-to-announce-0-76-eps.html.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply